Comparative activities of sitafloxacin against recent clinical isolates in hospitals across China

Asakura T, Suzuki S, Fukano H et al (2019) Sitafloxacin-containing regimen for the treatment of refractory Mycobacterium avium complex lung disease. Open Forum Infect Dis 6:ofz108

Manosuthi W, Wiboonchutikul S (2016) Treatment outcomes of oral sitafloxacin in acute complicated urinary tract infection and pyelonephritis. Springerplus 5:410

Keating GM (2011) Sitafloxacin: in bacterial infections. Drugs 71:731–744

Hamasuna R, Ohnishi M, Matsumoto M et al (2018) In Vitro activity of sitafloxacin and additional newer generation fluoroquinolones against ciprofloxacin-resistant Neisseria gonorrhoeae isolates. Microb Drug Resist 24:30–34

Tantisiriwat W, Linasmita P (2017) In vitro activity of sitafloxacin and other antibiotics against bacterial isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital. J Med Assoc Thail 100:469–478

Xu N, Wang G, Leng Y et al (2018) Sulbactam enhances the in vitro activity of sitafloxacin against extensively-drug resistant Acinetobacter baumannii. ExpTher Med 16:3485–3491

Clinical and Laboratory Standards Institute (2020) Performance standards for antimicrobial susceptibility testing; M100 30th. Clin Lab Stand Instit

CLSI (2018) M07, 11th Ed. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Clinical and Laboratory Standards Institute, Wayne

CLSI (2011) Methods for antimicrobial susceptibility testing for human mycoplasmas; approved guideline (M43-A). Clinical and Laboratory Standards Institute, Wayne

Hu F, Guo Y, Yang Y et al (2019) Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis 38:2275–2281

Milatovic D, Schmitz FJ, Brisse S, Verhoef J, Fluit AC (2000) In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother 44:1102–1107

Schmitz FJ, Fluit AC, Milatovic D et al (2000) In vitro potency of moxifloxacin, clinafloxacin and sitafloxacin against 248 genetically defined clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 46:109–113

Amano A, Matsuzaki K, Kishi N et al (2013) In vitro activity of sitafloxacin against clinical isolates in 2012. Jpn J Antibiot 66:311–330 [Japanese]

Doern GV, Heilmann KP, Huynh HK et al (2001) Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 45:1721–1729

Snydman DR, Jacobus NV, McDermott LA et al (2002) In vitro activities of newer quinolones against Bacteroides group organisms [Errata in Antimicrob Agents Chemother 2003;47(2):831]. Antimicrob Agents Chemother 46:3276–3279

Tanigawara Y, Kaku M, Totsuka K, Tsuge H, Saito A (2013) Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections. J Infect Chemother 19:858–866